Why You Should Buy Choline Supplements
This review will help you decide whether or not you are the right person to buy choline supplements products. The truth is, that many people have had positive experiences with Choline in improving cognitive performance and treating behavioural disorders.
Click here To Read Our Alpha GPC Spplement Review
“Great for improving ability to concentrate and retain information”
Choline is member of the B vitamin family, and is an essential component of a healthy diet, found in eggs, vegetable and soy. The reason Choline is an important dietary component is that it plays a prominent role in brain development, having a significant role in the structural integrity and signaling roles for brain cell membranes.
Despite the fact that Choline supplements are an essential dietary requirement, because it is often found in fatty meat and eggs, it’s consumption has declined in recent years due to the emergence of low-fat diets. In fact, studies have shown that on average, consumption of choline is lower than adequate.
Choline is essentially one of the ‘building block’ molecules for the neurotransmitter acetylcholine. This neurotransmitter is responsible for regulating things like muscle control and memory. Furthermore, it is used throughout the body in the construction of cell membranes.
Choline is a dietary supplement, and it is currently legal to buy choline without a prescription in the United States.
Click Here To Read Citicoline Benefits Review
Who should buy choline Supplements
So, we’ve determined that choline supplements can have health benefits, but are they applicable you? First, it important to note that certain people are more at risk of choline deficiency than others, including: athletes, vegetarians and people who consumer a lot of alcohol. Furthermore, choline is designed toimprove cognitive performance, and has been used in treating neurological disorders, such as ADHD.
So it’s clear that choline can be beneficial to both healthy individuals, and those with neurological disorders. Therefore, if the following kinds of people present as those who are most likely to benefit from choline use:
- Any healthy individual looking to improve concentration, focus or memory retention
- Those with disorders such as ADHD
- Alcohol consumers
Click Here To Read Our Review On Choline Bitartrate
If you would like a comprehensive list of customer feedback for Choline supplements products on Amazon, click here. Below are just some examples of the great things people have had to say about Choline.
“I rate this product so highly because I have experimented for a while for help with my son’s ADHD. This product does not solve the whole problem, but it is one element of success. It helps to reduce anxiety and bring about an overall calm and together-mindedness.”
“This product is great for improving ability to concentrate and retain technical data and information. It provides a mild energy boost within 30 minutes and the ability to focus and concentrate last for a full day.”
“This is the best formula I have found on the OTC market. I have tried to put a few together myself and nothing compares to this one. Especially good for retention and test performance. I have noticed that I need 1-2 hours less sleep per night as well. I have been using this one for 5+ years. A+++”
Levin, O. et. al., Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments, Neuroscience and Behavioral Physiology, 41 (1), pp.47-51 (2011)
Zh. M. Glozman, Quantitative Assessment of Neuropsychological Study Data [in Russian], Moscow (1999).V. V. Zakharov, I. V. Damulin, and N. N. Yakhno, “Cognitive impairments in patients with Parkinson’s disease,” Zh. Nevrol. Psikhiat., 1, 13–19 (2005).
O. S. Levin, “Mental disorders in patients with Parkinson’s disease and their correction,” in: Extrapyramidal Disorders. Handbook for Diagnosis and Treatment [in Russian], Medpress-Inform, Moscow (2002), pp. 125–151.
O. S. Levin and N. V. Fedorova, Parkinson’s Disease [in Russian], Moscow (2006).
O. S. Levin, L. A. Batukaeva, and I. G. Smolentseva, “Diagnosis and treatment of dementia in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 6, 85–91 (2008).
I. V. Litvinenko, Parkinson’s Disease [in Russian], Moscow (2006).
A. R. Luriya, Higher Cortical Functions in Humans and theirImpairments in Local Brain Lesions [in Russian], Moscow State University, Moscow (1969).
A. Yu. Panasyuk, An Adapted Variant of the Wechsler Test [in Russian], Research Institute Psychiatry, Moscow (1983).
D. Aarsland, K. Andersen, J. P. Larsen, et al., “Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study,” Arch. Neurol., 60, 387–392 (2003).
F. Amenta, L. Parnetti,V. Gallasi, et al., “Treatment of cognitive dysfunction associated with Alzheimer disease with cholinergic precursors,” Mech. Aging Dev., 122, 2025 (2001).
R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers (2003).
J. L. Cummings, “Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 76, 903–904 (2005).
M. Emre, D. Aarsland, A. Albanese, et al., “Rivastigmine for dementia associated with Parkinson’s disease,” New Engl. J. Med., 351, 2509–2518 (2004).
M. Emre, D. Aarsland, R. Brown, et al., “Clinical diagnostic criteria for dementia associated with Parkinson disease,” Mov. Dis., 22, 1689–1707 (2007).
S. Fahn and R. L. Elton, “Unified Rating Scale for Parkinson’s Disease,” in: Recent developments in Parkinson’s Disease, S. Fahn and C. D. Marsden (eds.), Macmillan, Florham Park, New York, pp. 153–163.
M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental status,” J. Psychiat. Res., 12, 189–196 (1975).
W. Gibb and A. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 51, 745–752 (1988).
M. A. Hely, J. G. Morris, W. G. Reid, et al., “Sydney multicenter study of Parkinson’s disease,” Mov. Dis., 23, 837–844 (2008).
M. Hoehn and M. D. Jahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967).
H. Lehfeld and H. Erzigkeit, “The SKT-A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention,” Int. Psychogeriat., 9, 115–121 (1997).
P. J. Manos and R. Wu, “The ten point clock test,” Int. J. Psych. Med., 24, 229–244 (1994).
L. Parnetti, F. Mignini, D. Tomasssoni, et al., “Cholinergic precursors in the treatment of cognitive impairment of vascular origin,” J. Neurol. Sci., 257, 264–269 (2007).
E. Perry, M. Walker, J. Grace, and R. Perry, “Acetylcholine in mind: a neurotransmitter correlate of consciousness?” Trends Neurosci., 22, 273–280 (1999)
S. E. Starkstein and M. Merello, Psychiatric and Cognitive Disorders in Parkinson’s Disease, Cambridge University Press, Cambridge (2002).
(links on this page are sponsored affiliate links. The owner makes commission if you buy after clicking these links. The owner is not necessarily a user of this product. However, he has thoughroughly researched it, and is providing his personal opinion only)